Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07199569 · ClinicalTrials.gov registry record · Phase 2
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
A Phase 2 study of Monkeypox (Mpox), sponsored by Bavarian Nordic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 744
- Enrollment target
- 10
- Study locations
NCT07199569: Recruiting Phase 2 study of Monkeypox (Mpox), sponsored by Bavarian Nordic.
NCT07199569 is a Phase 2 study of Monkeypox (Mpox) that is actively recruiting participants, run by Bavarian Nordic. The registered enrollment target is 744 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (459% higher). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07199569, a Phase 2 study of Monkeypox (Mpox), is actively recruiting participants, sponsored by Bavarian Nordic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 744 participants
- Enrollment target
- 10
- Study locations
Study Summary
andomized, double-blind, phase 2b trial to assess comparability in immunogenicity, safety, and reactogenicity of MVA-BN vaccine manufactured in primary chicken embryo fibroblast (CEF) cells and the CCX.E10 quail cell line in adults
Primary Outcome
Titer of serum neutralizing antibodies against vaccinia virus as measured by plaque reduction neutralization tests (PRNTs)
Conditions Studied
Interventions
- BIOLOGICAL Jynneos
- BIOLOGICAL MVA-BN (Quail)
Study Locations (10)
North Carolina
- Accellacare of Cary - Cary Medical Group - Cary
- Accellacare Research of Salisbury - Salisbury
Texas
- Avacare - Austin
- Avacare - Fort Worth
Iowa
- Accellacare and McFarland Clinic - Ames
Kansas
- Johnson County ClinTrials, LLC - Lenexa
New York
- Rochester Clinical Research, Inc - Rochester
South Carolina
- Accellacare of Charleston - Mt. Pleasant
Tennessee
- Accellacare - Knoxville - Knoxville
Virginia
- Velocity Clinical Research - Suffolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 744 participants |
| Start Date | 2025-10-27 |
| Est. Completion | 2026-10-31 |
| Phase | Phase 2 |
What NCT07199569 shows while recruiting
NCT07199569 is an interventional study that assigns participants to a tested intervention. The registered 744 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (459% higher).
The record links to 1 condition, with Monkeypox (Mpox) appearing as the primary indexed condition, and to 2 interventions - of which Jynneos is the first listed.
NCT07199569 lists 10 locations in 8 states (North Carolina, Texas, Iowa).
Frequently Asked Questions
What is clinical trial NCT07199569 about?
NCT07199569 is a clinical study titled "Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells". andomized, double-blind, phase 2b trial to assess comparability in immunogenicity, safety, and reactogenicity of MVA-BN vaccine manufactured in primary chicken embryo fibroblast (CEF) cells and the CCX.E10 quail cell line in adults
What is the current status of trial NCT07199569?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 744 participants. The study started on 2025-10-27. Estimated completion is 2026-10-31.
What conditions does trial NCT07199569 study?
This clinical trial studies the following conditions: Monkeypox (Mpox).
What interventions are being tested in trial NCT07199569?
The interventions under investigation include: Jynneos (BIOLOGICAL), MVA-BN (Quail) (BIOLOGICAL).
Who is sponsoring clinical trial NCT07199569?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07199569 being conducted?
This trial has 10 study locations across Iowa, Kansas, New York, North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07199569's enrollment target sits among peer trials
744 44th of 2000 higher than 1,957 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05619185 · 744 participants · NA
A SMART Evaluation of an Adaptive Web-based AUD Treatment for Service Members and Their Partners
- NCT06417814 · 744 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT07046351 · 744 participants · NA
weSIPsmarter: Evaluating a Digital Health Intervention Aimed at Reducing Sugary Drinks Among Rural Head Start Preschoolers and Their Parents
- NCT05786417 · 741 participants · Phase 4
LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI